

Direct Healthcare Professional Communication

27-October-2020

DARZALEX® (daratumumab): New Identified Risk of Hepatitis B Reactivation

Dear Healthcare Professional,

Janssen Egypt in agreement with the Egyptian Pharmacovigilance Center (EPVC) would like to inform you about a new adverse drug reaction (ADR)/important identified risk of Hepatitis B (HBV) reactivation associated with the use of DARZALEX® (daratumumab).

Summary

Hepatitis B virus (HBV) reactivation, in some cases fatal, has been reported in patients treated with DARZALEX® (daratumumab).

Recommendations

- HBV screening should be performed in all patients before initiation of treatment with DARZALEX® (daratumumab).
- For patients with evidence of positive HBV serology, monitor for clinical and laboratory signs of HBV reactivation during, and for at least six months following the end of DARZALEX® (daratumumab) treatment. Manage patients according to clinical guidelines.
- In patients who develop reactivation of HBV while on DARZALEX® (daratumumab), suspend treatment with DARZALEX® (daratumumab) and any concomitant steroids, chemotherapy, and institute appropriate treatment. Resumption of DARZALEX® (daratumumab) treatment in patients whose HBV reactivation is adequately controlled should be discussed with physicians with expertise in managing HBV.

Background

A recent cumulative review of data from clinical trials and post-marketing cases has identified reports of HBV reactivation in patients treated with DARZALEX® (daratumumab). As of 15 November 2018, DARZALEX® (daratumumab) has been received by approximately 4407 patients in the setting of clinical trials, and an estimated world-wide post-marketing exposure of 34,316 person-years. The overall frequency of HBV reactivation in DARZALEX® (daratumumab) clinical trials, including serious and non-serious reports, is uncommon (0.2%). The majority of clinical trial cases were considered non-serious, although fatal HBV reactivation cases have been reported in clinical trials and in the post-marketing setting. DARZALEX® (daratumumab) has been continued once HBV reactivation has been controlled with antiviral medication.

The role of DARZALEX® (daratumumab) therapy in the reported cases of HBV reactivation is confounded by the underlying medical condition given that patients with multiple myeloma are immunosuppressed. In several cases patients were also receiving concomitant medications associated with viral reactivation. However, as the relationship cannot be ruled out, the Prescribing Information and the Patient

Information Leaflet for DARZALEX® (daratumumab) updated and reflected the new safety information.

Call for reporting

Healthcare professionals should report suspected adverse reactions associated with this product in accordance with the national spontaneous reporting system.

- **Egyptian Pharmaceutical Vigilance Center (EPVC) - Egyptian Drug Authority (EDA)**
21 Abd Elaziz Al Souad st. – Manial El-Roda – Cairo, PO Box: 11451
Tel: +202 – 25354100 +202 – 23684288 +202 – 23648046 +202 – 23640368 +202 – 23640369
Extension (Tel): 1303 **Fax:** +202 23684194
Website: www.epvc.gov.eg
E-mail: pv.center@eda.mohealth.gov.eg

Company contact points

If you have further questions or require additional information, please contact

- **Janssen Egypt Scientific Office**

Address: Building 44, North Teseen street, 5th settlement, New Cairo, P.O Box 11835, Cairo, Egypt
Email: JACEG-PV@its.jnj.com
Tel: +2 21291100 /+221291199 **Mobile:** +2 01000629760